Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: A meta-analysis

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 3, 2016, Pages 183-193

  Abdel Rahman, Omar ^a   Fouad, Mona ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

ipilimumab; nivolumab; NSCLC; pembrolizumab; pneumonitis

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG CANCER; META ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHEMICALLY INDUCED; COMPARATIVE STUDY; NEOPLASMS; PATHOLOGY; RISK;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASMS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84973573023     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816636557     Document Type: Article

References (44)

1. Abdel-Rahman O., (2016) Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit Rev Oncol Hematol 97: 65-71.
2. Abdel-Rahman O., ElHalawani H., (2015d) Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncol 11: 1109-1122.
3. Abdel-Rahman O., ElHalawani H., Fouad M., (2015a) Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 7: 1213-1227.
4. Abdel-Rahman O., ElHalawani H., Fouad M., (2015b) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 11: 2471-2484.
5. Abdel-Rahman O., ElHalawani H., Fouad M., (2015c) Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin Drug Saf 14: 1507-1518.
6. Abdel-Rahman O., ElHalawani H., Fouad M., (2016) Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol 12: 413-425.
7. Alegre M., Noel P., Eisfelder B., Chuang E., Clark M., Reiner S., et al. (1996) Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 157: 4762-4770.
8. Armand P., Nagler A., Weller E., Devine S., Avigan D., Chen Y., et al. (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31: 4199-4206.
9. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Research 14: 3044-3051.
10. Borghaei H., Paz-Ares L., Horn L., Spigel D., Steins M., Ready N., et al. (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med 373: 1627-1639.
11. Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W., Poddubskaya E., et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Engl J Med 373: 123-135.
12. Brahmer J., Tykodi S., Chow L., Hwu W., Topalian S., Hwu P., et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 366: 2455-2465.
13. Bronstein Y., Ng C., Hwu P., Hwu W., (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol 197: W992-W1000.
14. Chow L., (2013) Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. In: Dizon D., (ed.), American Society of Clinical Oncology 2013 Educational Book. Alexandria, VA: American Society of Clinical Oncology, e280.
15. Corsello S., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F., (2013) Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98: 1361-1375.
16. Garon E., Rizvi N., Hui R., Leighl N., Balmanoukian A., Eder J., et al. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med 372: 2018-2028.
17. Grande C., Villanueva M., Huidobro G., Casal J., (2007) Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9: 578-581.
18. Guibert N., Delaunay M., Mazières J., (2015) Targeting the immune system to treat lung cancer: rationale and clinical experience. Ther Adv Respir Dis 9: 105-120.
19. Hamid O., Robert C., Daud A., Hodi F., Hwu W., Kefford R., et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med 369: 134-144.
20. Herbst R., Baas P., Kim D., Felip E., Pérez-Gracia J., Han J., et al. (2015) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. DOI: http://dx.doi.org/10.1016/S0140-6736(15)01281-7.
21. Hodi F., O'Day S.J., McDermott D., Weber R., Sosman J., Haanen J., et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 363: 711-723.
22. Intlekofer A., Thompson C., (2013) At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukocyte Biol 94: 25-39.
23. Jadad A., Moore R., Carroll D., Jenkinson C., Reynolds D., Gavaghan D., et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 17: 1-12.
24. Kwon E., Drake C., Scher H., Fizazi K., Bossi A., van den Eertwegh A., et al. (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15: 700-712.
25. Lai Y., Lin P., Lai J., Hsu S., Kuo L., Chang S., et al. (2011) Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Int J Clin Pharmacol Ther 49: 461-466.
26. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J., Cowey C., Lao C., et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl J Med 373: 23-34.
27. Moher D., Liberati A., Tetzlaff J., Altman D., (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann Intern Med 151: 264-269.
28. Momtaz P., Postow M., (2014) Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics Pers Med 7: 357.
29. Motzer R., Escudier B., McDermott D., George S., Hammers H., Srinivas S., et al. (2015) Nivolumab versus eerolimus in advanced renal-cell carcinoma. N Eng J Med 373: 1803-1813.
30. Nishino M., Sholl L., Hatabu H., Ramaiya N., Hodi F., (2015) Anti-PD-1-related pneumonitis during cancer immunotherapy. New Engl J Med 373: 288-290.
31. Postow M., Chesney J., Pavlick A., Robert C., Grossmann K., McDermott D., et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl J Med 372: 2006-2017.
32. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C., et al. (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16: 908-918.
33. Robert C., Long G., Brady B., Dutriaux C., Maio M., Mortier L., et al. (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. New Engl J Med 372: 320-330.
34. Robert C., Schachter J., Long G., Arance A., Grob J., Mortier L., et al. (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. New Engl J Med 372: 2521-2532.
35. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 364: 2517-2526.
36. Rosenberg S., Yang J., Restifo N., (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
37. Roychowdhury D., Cassidy C., Peterson P., Arning M., (2002) A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 20: 311-315.
38. Spira A., Park K., Mazieres J., Vansteenkiste J., Rittmeyer A., Ballinger M., (2015) Efficacy, safety and predictive biomarker results from a randomized phase ii study comparing atezolizumab (MPDL3280a) vs docetaxel in 2l/3l NSCLC (Poplar). J Clin Oncol 33 (suppl.): abstract 8010.
39. Tirumani S., Ramaiya N., Keraliya A., Bailey N., Ott P., Hodi F., et al. (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3: 1185-1192.
40. Topalian S., Hodi F., Brahmer J., Gettinger S., Smith D., McDermott D., et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 366: 2443-2454.
41. Torino F., Barnabei A., Paragliola R., Marchetti P., Salvatori R., Corsello S., (2013) Endocrine side-effects of anti-cancer drugs: mabs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 169: R153-R164.
42. Weber J., D'angelo S., Minor D., Hodi F., Gutzmer R., Neyns B., et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 TREATMENT (CHECKMATE 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384.
43. Weber J., Kähler K., Hauschild A., (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697.
44. Westin J., Chu F., Zhang M., Fayad L., Kwak L., Fowler N., et al. (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15: 69-77.